{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,26]],"date-time":"2025-11-26T16:15:45Z","timestamp":1764173745519,"version":"build-2065373602"},"reference-count":48,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2011,9,1]],"date-time":"2011-09-01T00:00:00Z","timestamp":1314835200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2011,9,1]],"date-time":"2011-09-01T00:00:00Z","timestamp":1314835200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Endocrinology and Metabolism Clinics of North America"],"published-print":{"date-parts":[[2011,9]]},"DOI":"10.1016\/j.ecl.2011.05.006","type":"journal-article","created":{"date-parts":[[2011,7,13]],"date-time":"2011-07-13T01:01:33Z","timestamp":1310518893000},"page":"509-518","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":14,"title":["Postmenopausal Hormone Therapy and Breast Cancer Risk: Current Status and Unanswered Questions"],"prefix":"10.1016","volume":"40","author":[{"given":"Wendy Y.","family":"Chen","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ecl.2011.05.006_bib1","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1111\/j.1365-2125.2005.02502.x","article-title":"Dramatic change in prescribing of hormone replacement therapy in The Netherlands after publication of the Million Women Study: a follow-up study","volume":"60","author":"Faber","year":"2005","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.ecl.2011.05.006_bib2","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1001\/jama.291.1.47","article-title":"National use of postmenopausal hormone therapy: annual trends and response to recent evidence","volume":"291","author":"Hersh","year":"2004","journal-title":"JAMA"},{"key":"10.1016\/j.ecl.2011.05.006_bib3","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1007\/s00228-007-0320-6","article-title":"Prescribing of hormone therapy for menopause, tibolone, and bisphosphonates in women in the UK between 1991 and 2005","volume":"63","author":"Watson","year":"2007","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1016\/j.ecl.2011.05.006_bib4","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1001\/jama.288.3.321","article-title":"Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women\u2019s Health Initiative randomized controlled trial","volume":"288","author":"Rossouw","year":"2002","journal-title":"JAMA"},{"key":"10.1016\/j.ecl.2011.05.006_bib5","doi-asserted-by":"crossref","first-page":"1701","DOI":"10.1001\/jama.291.14.1701","article-title":"Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women\u2019s Health Initiative randomized controlled trial","volume":"291","author":"Anderson","year":"2004","journal-title":"JAMA"},{"key":"10.1016\/j.ecl.2011.05.006_bib6","doi-asserted-by":"crossref","first-page":"3243","DOI":"10.1001\/jama.289.24.3243","article-title":"Influence of estrogen plus progestin on breast cancer and mammography in healthy postmenopausal women: the Women\u2019s Health Initiative Randomized Trial","volume":"289","author":"Chlebowski","year":"2003","journal-title":"JAMA"},{"key":"10.1016\/j.ecl.2011.05.006_bib7","doi-asserted-by":"crossref","first-page":"1366","DOI":"10.1093\/jnci\/dji279","article-title":"Estrogen-plus-progestin use and mammographic density in postmenopausal women: Women\u2019s Health Initiative randomized trial","volume":"97","author":"McTiernan","year":"2005","journal-title":"J\u00a0Natl Cancer Inst"},{"key":"10.1016\/j.ecl.2011.05.006_bib8","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1001\/archinternmed.2007.123","article-title":"Estrogen plus progestin and breast cancer detection by means of mammography and breast biopsy","volume":"168","author":"Chlebowski","year":"2008","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.ecl.2011.05.006_bib9","doi-asserted-by":"crossref","first-page":"R8","DOI":"10.1186\/bcr1364","article-title":"Hormone replacement therapy and false positive recall in the Million Women Study: patterns of use, hormonal constituents and consistency of effect","volume":"8","author":"Banks","year":"2006","journal-title":"Breast Cancer Res"},{"key":"10.1016\/j.ecl.2011.05.006_bib10","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1056\/NEJMoa0807684","article-title":"Breast cancer after use of estrogen plus progestin in postmenopausal women","volume":"360","author":"Chlebowski","year":"2009","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.ecl.2011.05.006_bib11","doi-asserted-by":"crossref","first-page":"1647","DOI":"10.1001\/jama.295.14.1647","article-title":"Effects of conjugated equine estrogens on breast cancer and mammography screening in postmenopausal women with hysterectomy","volume":"295","author":"Stefanick","year":"2006","journal-title":"JAMA"},{"key":"10.1016\/j.ecl.2011.05.006_bib12","doi-asserted-by":"crossref","first-page":"6135","DOI":"10.1200\/JCO.2008.21.7166","article-title":"Conjugated equine estrogen influence on mammographic density in postmenopausal women in a substudy of the Women\u2019s Health Initiative randomized trial","volume":"27","author":"McTiernan","year":"2009","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.ecl.2011.05.006_bib13","doi-asserted-by":"crossref","first-page":"2690","DOI":"10.1200\/JCO.2009.24.8799","article-title":"Estrogen alone in postmenopausal women and breast cancer detection by means of mammography and breast biopsy","volume":"28","author":"Chlebowski","year":"2010","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.ecl.2011.05.006_bib14","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1016\/S0140-6736(97)08233-0","article-title":"Breast cancer and hormone replacement therapy: collaborative reanalysis of data from 51 epidemiological studies of 52,705 women with breast cancer and 108,411 women without breast cancer. Collaborative Group on Hormonal Factors in Breast Cancer","volume":"350","year":"1997","journal-title":"Lancet"},{"key":"10.1016\/j.ecl.2011.05.006_bib15","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1016\/S0140-6736(03)14596-5","article-title":"Breast cancer and hormone-replacement therapy in the Million Women Study","volume":"362","author":"Beral","year":"2003","journal-title":"Lancet"},{"key":"10.1016\/j.ecl.2011.05.006_bib16","doi-asserted-by":"crossref","first-page":"855","DOI":"10.7326\/0003-4819-142-10-200505170-00011","article-title":"Hormone therapy for the prevention of chronic conditions in postmenopausal women: recommendations from the U.S. Preventive Services Task Force","volume":"142","year":"2005","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.ecl.2011.05.006_bib17","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1097\/AOG.0b013e31818e8782","article-title":"ACOG Committee Opinion No. 420, November 2008: hormone therapy and heart disease","volume":"112","year":"2008","journal-title":"Obstet Gynecol"},{"key":"10.1016\/j.ecl.2011.05.006_bib18","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1016\/j.maturitas.2008.10.009","article-title":"The EMAS 2008 update on clinical recommendations on postmenopausal hormone replacement therapy","volume":"61","author":"Gompel","year":"2008","journal-title":"Maturitas"},{"key":"10.1016\/j.ecl.2011.05.006_bib19","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1097\/gme.0b013e3181d0f6b9","article-title":"Estrogen and progestogen use in postmenopausal women: 2010 position statement of The North American Menopause Society","volume":"17","year":"2010","journal-title":"Menopause"},{"key":"10.1016\/j.ecl.2011.05.006_bib20","doi-asserted-by":"crossref","first-page":"1465","DOI":"10.1001\/jama.297.13.1465","article-title":"Postmenopausal hormone therapy and risk of cardiovascular disease by age and years since menopause","volume":"297","author":"Rossouw","year":"2007","journal-title":"JAMA"},{"key":"10.1016\/j.ecl.2011.05.006_bib21","doi-asserted-by":"crossref","first-page":"5138","DOI":"10.1200\/JCO.2008.21.6432","article-title":"Estrogen-progestagen menopausal hormone therapy and breast cancer: does delay from menopause onset to treatment initiation influence risks?","volume":"27","author":"Fournier","year":"2009","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.ecl.2011.05.006_bib22","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1007\/s12265-009-9104-y","article-title":"Using basic science to design a clinical trial: baseline characteristics of women enrolled in the Kronos Early Estrogen Prevention Study (KEEPS)","volume":"2","author":"Miller","year":"2009","journal-title":"J\u00a0Cardiovasc Transl Res"},{"key":"10.1016\/j.ecl.2011.05.006_bib23","doi-asserted-by":"crossref","first-page":"1684","DOI":"10.1001\/jama.2010.1500","article-title":"Estrogen plus progestin and breast cancer incidence and mortality in postmenopausal women","volume":"304","author":"Chlebowski","year":"2010","journal-title":"JAMA"},{"key":"10.1016\/j.ecl.2011.05.006_bib24","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1038\/ncponc0851","article-title":"Risk factors and hormone-receptor status: epidemiology, risk-prediction models and treatment implications for breast cancer","volume":"4","author":"Chen","year":"2007","journal-title":"Nat Clin Pract Oncol"},{"key":"10.1016\/j.ecl.2011.05.006_bib25","doi-asserted-by":"crossref","first-page":"1687","DOI":"10.1016\/S0140-6736(05)66544-0","article-title":"Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials","volume":"365","year":"2005","journal-title":"Lancet"},{"key":"10.1016\/j.ecl.2011.05.006_bib26","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1001\/archinte.166.9.1027","article-title":"Unopposed estrogen therapy and the risk of invasive breast cancer","volume":"166","author":"Chen","year":"2006","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.ecl.2011.05.006_bib27","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1093\/jnci\/djn075","article-title":"Conjugated equine estrogen and risk of benign proliferative breast disease: a randomized controlled trial","volume":"100","author":"Rohan","year":"2008","journal-title":"J\u00a0Natl Cancer Inst"},{"key":"10.1016\/j.ecl.2011.05.006_bib28","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1007\/s10549-007-9523-x","article-title":"Unequal risks for breast cancer associated with different hormone replacement therapies: results from the E3N cohort study","volume":"107","author":"Fournier","year":"2008","journal-title":"Breast Cancer Res Treat"},{"key":"10.1016\/j.ecl.2011.05.006_bib29","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1002\/ijc.20016","article-title":"Increased risk of breast cancer following different regimens of hormone replacement therapy frequently used in Europe","volume":"109","author":"Stahlberg","year":"2004","journal-title":"Int J Cancer"},{"key":"10.1016\/j.ecl.2011.05.006_bib30","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1097\/AOG.0b013e31818e8cd6","article-title":"Breast cancer risk in postmenopausal women using estradiol-progestogen therapy","volume":"113","author":"Lyytinen","year":"2009","journal-title":"Obstet Gynecol"},{"key":"10.1016\/j.ecl.2011.05.006_bib31","doi-asserted-by":"crossref","first-page":"1483","DOI":"10.1001\/archinte.166.14.1483","article-title":"Combined estrogen and testosterone use and risk of breast cancer in postmenopausal women","volume":"166","author":"Tamimi","year":"2006","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.ecl.2011.05.006_bib32","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1001\/archinternmed.2008.507","article-title":"Influence of estrogen plus testosterone supplementation on breast cancer","volume":"169","author":"Ness","year":"2009","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.ecl.2011.05.006_bib33","doi-asserted-by":"crossref","first-page":"832","DOI":"10.1002\/ijc.2910420606","article-title":"Influence of non-contraceptive exogenous and endogenous sex hormones on breast cancer risk in Denmark","volume":"42","author":"Ewertz","year":"1988","journal-title":"Int J Cancer"},{"key":"10.1016\/j.ecl.2011.05.006_bib34","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1093\/jnci\/dji132","article-title":"Serum sex steroids in premenopausal women and breast cancer risk within the European Prospective Investigation into Cancer and Nutrition (EPIC)","volume":"97","author":"Kaaks","year":"2005","journal-title":"J\u00a0Natl Cancer Inst"},{"key":"10.1016\/j.ecl.2011.05.006_bib35","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1093\/jnci\/94.8.606","article-title":"Endogenous sex hormones and breast cancer in postmenopausal women: reanalysis of nine prospective studies","volume":"94","author":"Key","year":"2002","journal-title":"J\u00a0Natl Cancer Inst"},{"key":"10.1016\/j.ecl.2011.05.006_bib36","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1002\/ijc.20710","article-title":"Breast cancer risk in relation to different types of hormone replacement therapy in the E3N-EPIC cohort","volume":"114","author":"Fournier","year":"2005","journal-title":"Int J Cancer"},{"key":"10.1016\/j.ecl.2011.05.006_bib37","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1054\/bjoc.2001.1899","article-title":"A\u00a0population-based cohort study of HRT use and breast cancer in southern Sweden","volume":"85","author":"Olsson","year":"2001","journal-title":"Br J Cancer"},{"key":"10.1016\/j.ecl.2011.05.006_bib38","doi-asserted-by":"crossref","first-page":"973","DOI":"10.7326\/0003-4819-127-11-199712010-00004","article-title":"The role of hormone replacement therapy in the risk for breast cancer and total mortality in women with a family history of breast cancer","volume":"127","author":"Sellers","year":"1997","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.ecl.2011.05.006_bib39","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1097\/EDE.0b013e3181a71279","article-title":"Hormone replacement therapy, family history, and breast cancer risk among postmenopausal women","volume":"20","author":"Gramling","year":"2009","journal-title":"Epidemiology"},{"key":"10.1016\/j.ecl.2011.05.006_bib40","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1002\/(SICI)1097-0215(19990505)81:3<339::AID-IJC5>3.0.CO;2-6","article-title":"Breast-cancer risk following long-term oestrogen- and oestrogen-progestin-replacement therapy","volume":"81","author":"Magnusson","year":"1999","journal-title":"Int J Cancer"},{"key":"10.1016\/j.ecl.2011.05.006_bib41","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1001\/jama.283.4.485","article-title":"Menopausal estrogen and estrogen-progestin replacement therapy and breast cancer risk","volume":"283","author":"Schairer","year":"2000","journal-title":"JAMA"},{"key":"10.1016\/j.ecl.2011.05.006_bib42","doi-asserted-by":"crossref","first-page":"3150","DOI":"10.1158\/1055-9965.EPI-08-0435","article-title":"Menopausal hormone therapy and breast cancer risk in the NIH-AARP Diet and Health Study Cohort","volume":"17","author":"Brinton","year":"2008","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"10.1016\/j.ecl.2011.05.006_bib43","doi-asserted-by":"crossref","first-page":"910","DOI":"10.1016\/S1470-2045(06)70911-1","article-title":"Million Women Study Collaborators. Hormonal therapy for menopause and breast-cancer risk by histological type: a cohort study and meta-analysis","volume":"7","author":"Reeves","year":"2006","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ecl.2011.05.006_bib44","doi-asserted-by":"crossref","first-page":"3830","DOI":"10.1200\/JCO.2009.26.4770","article-title":"Breast cancer risk by breast density, menopause, and postmenopausal hormone therapy use","volume":"28","author":"Kerlikowske","year":"2010","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.ecl.2011.05.006_bib45","doi-asserted-by":"crossref","first-page":"1817","DOI":"10.1002\/cncr.10913","article-title":"Estrogen replacement therapy for menopausal women with a history of breast carcinoma: results of a 5-year, prospective study","volume":"95","author":"Vassilopoulou-Sellin","year":"2002","journal-title":"Cancer"},{"key":"10.1016\/j.ecl.2011.05.006_bib46","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1093\/jnci\/dji071","article-title":"Menopausal hormone therapy after breast cancer: the Stockholm randomized trial","volume":"97","author":"von Schoultz","year":"2005","journal-title":"J\u00a0Natl Cancer Inst"},{"issue":"7","key":"10.1016\/j.ecl.2011.05.006_bib47","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1093\/jnci\/djn058","article-title":"Increased risk of recurrence after hormone replacement therapy in breast cancer survivors","volume":"100","author":"Holmberg","year":"2008","journal-title":"J\u00a0Natl Cancer Inst"},{"key":"10.1016\/j.ecl.2011.05.006_bib48","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/S1470-2045(08)70341-3","article-title":"Safety and efficacy of tibolone in breast-cancer patients with vasomotor symptoms: a double-blind, randomised, non-inferiority trial","volume":"10","author":"Kenemans","year":"2009","journal-title":"Lancet Oncol"}],"container-title":["Endocrinology and Metabolism Clinics of North America"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0889852911000557?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0889852911000557?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T09:35:14Z","timestamp":1760175314000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0889852911000557"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,9]]},"references-count":48,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2011,9]]}},"alternative-id":["S0889852911000557"],"URL":"https:\/\/doi.org\/10.1016\/j.ecl.2011.05.006","relation":{},"ISSN":["0889-8529"],"issn-type":[{"type":"print","value":"0889-8529"}],"subject":[],"published":{"date-parts":[[2011,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Postmenopausal Hormone Therapy and Breast Cancer Risk: Current Status and Unanswered Questions","name":"articletitle","label":"Article Title"},{"value":"Endocrinology and Metabolism Clinics of North America","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ecl.2011.05.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2011 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}